DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,506,583 | +4.8% | 14,134 | +1.4% | 0.18% | +3.4% |
| Q2 2023 | $3,346,252 | +0.6% | 13,943 | +5.7% | 0.18% | -13.4% |
| Q1 2023 | $3,324,944 | -20.6% | 13,192 | -16.4% | 0.20% | -20.5% |
| Q4 2022 | $4,187,211 | +7.8% | 15,776 | +4.9% | 0.25% | -4.9% |
| Q3 2022 | $3,883,000 | -7.9% | 15,035 | -8.0% | 0.27% | +28.4% |
| Q2 2022 | $4,218,000 | -10.6% | 16,348 | +1.6% | 0.21% | +2.5% |
| Q1 2022 | $4,719,000 | +1.2% | 16,088 | +13.5% | 0.20% | +14.0% |
| Q4 2021 | $4,665,000 | +10.2% | 14,178 | +1.2% | 0.18% | +9.9% |
| Q3 2021 | $4,234,000 | +16.1% | 14,005 | +5.2% | 0.16% | +14.1% |
| Q2 2021 | $3,646,000 | -1.1% | 13,308 | -8.3% | 0.14% | +37.9% |
| Q1 2021 | $3,686,000 | +13.9% | 14,519 | -5.6% | 0.10% | -20.8% |
| Q4 2020 | $3,237,000 | +4.4% | 15,377 | +2.8% | 0.13% | -19.3% |
| Q3 2020 | $3,101,000 | +1.7% | 14,952 | -15.8% | 0.16% | -5.3% |
| Q2 2020 | $3,049,000 | +51.8% | 17,757 | +22.8% | 0.17% | +25.9% |
| Q1 2020 | $2,008,000 | -16.6% | 14,456 | -8.3% | 0.14% | +4.7% |
| Q4 2019 | $2,409,000 | +19.4% | 15,759 | +10.5% | 0.13% | +6.6% |
| Q3 2019 | $2,018,000 | +18.9% | 14,258 | +20.6% | 0.12% | +15.2% |
| Q2 2019 | $1,697,000 | +32.4% | 11,824 | +21.7% | 0.10% | +23.5% |
| Q1 2019 | $1,282,000 | +119.1% | 9,716 | +71.5% | 0.08% | +97.7% |
| Q4 2018 | $585,000 | +73.1% | 5,666 | +84.7% | 0.04% | +87.0% |
| Q3 2018 | $338,000 | +40.8% | 3,067 | +25.9% | 0.02% | +21.1% |
| Q2 2018 | $240,000 | +2.6% | 2,437 | +1.9% | 0.02% | -5.0% |
| Q1 2018 | $234,000 | +4.0% | 2,392 | -1.6% | 0.02% | 0.0% |
| Q4 2017 | $225,000 | +7.7% | 2,430 | -0.4% | 0.02% | -4.8% |
| Q3 2017 | $209,000 | +2.0% | 2,440 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $205,000 | -18.0% | 2,440 | -16.8% | 0.02% | -19.2% |
| Q1 2017 | $250,000 | +13.6% | 2,931 | +3.5% | 0.03% | -10.3% |
| Q4 2016 | $220,000 | +2.3% | 2,831 | +3.0% | 0.03% | 0.0% |
| Q3 2016 | $215,000 | -20.7% | 2,749 | +3.5% | 0.03% | -25.6% |
| Q2 2016 | $271,000 | -20.5% | 2,656 | -25.5% | 0.04% | -25.0% |
| Q1 2016 | $341,000 | – | 3,566 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |